CD19 and B-cell non-Hodgkin lymphoma: In recent years, anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) has shown significant clinical benefit in phase 3 trials for patients with aggressive B-cell lymphomas, in patients R/R to ≥2 lines of treatment (104–107) and, more recently, in second line in early relapse patients (108–110).